fig2

Endocrine therapy in metastatic breast cancer-more than just CDK4/6 inhibitors

Figure 2. Targeting the PI3K/AKT/mTOR pathway; Modified from Du Rusquec et al., 2020[69]. E: Estrogen; ER: estrogen receptor; GFR: growth factor receptor; PI3K: phosphatidylinositol-3 kinase; PI3Ki: phosphatidylinositol-3 kinase inhibitor; AKT: protein kinase B; AKTi: AKT kinase inhibitor; PTEN: phosphatase and tensin homolog; mTORC1/2: mammalian target of rapamycin complex 1/2; mTORC1/2i: mammalian target of rapamycin complex 1/2 inhibitor.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/